:157-165). For the CJ system, this presents not just a challenge but a unique opportunity to improve public health and public safety. In particular, medicationassisted treatments (MATs) have shown the potential to reduce both recidivism and relapse. Nevertheless, access to MAT in this setting remains limited; for example, although U.S. drug courts were created chiefly to expand access to drug addiction treatment services, only about one-half make MAT available (Matusow et al. 2013 , "Medication Assisted Treatment in US Drug Courts: Results from a Nationwide Survey of Availability, Barriers and Attitudes." Journal of Substance Abuse Treatment 44 (5):473-480). In this commentary, we explore the reasons for which access to MAT is limited in this setting, and lay out the evidence and arguments for a particular type of MAT: extended release (ER) naltrexone.
MAT Stigma
MAT encompasses two types of medications with distinct mechanisms of action: agonist-based MATs which bind to opioid receptors and activate them, and antagonist-based MATs which bind to the same receptors and block them. In the CJ setting, the underuse of MATs is partly due to its stigmatization as "one opiate for another." But this stigma is both overblown (relative to agonists) and overbroad (relative to antagonists). Although the efficacy of agonist-based MATs like methadone and buprenorphine in the CJ setting is well-established (Gordon et al. 2008; Magura et al. 2009 ), CJ professionals could still have legitimate concerns about their use. The first is the potential for abuse. If an opioid has both a rapid onset and a short duration of action, its potential for abuse is greatly increased. It is for this reason that agonist-based MATs have relatively long half-lives (eg., methadone's half-life, 24 hours, is substantially longer than heroin's, 30 minutes) and are administered either orally or sublingually, which slows absorption and limits abuse liability. Even so, agonist-based MATs are not foolproof: a person can still use them in a way (eg., by taking multiple doses or by opioid naïve individuals) that produces a "high." The second is risk for diversion. Because agonist-based MATs can potentially be used to get "high," they have street value, which is borne out by research on diversion of methadone and buprenorphine (Dasgupta et al. 2010; Johanson et al. 2012 ). The third is risk for overdose. While methadone poses a significantly greater risk than buprenorphine, both have potential for overdose, particularly when used in combination with other drugs such as benzodiazepines (e. g., diazepam, alprazolam) (Marteau, McDonald, and Patel 2015) . It is important to stress, however, that these are not compelling reasons to bar access to agonist-based MATs in the CJ setting; often the benefits of these drugs clearly outweigh the more serious risks of opiate misuse.
With regard to opioid antagonists like ER naltrexone, the "one opiate for another" stigma is fully misplaced. Such MATs lack the reinforcing properties of opioid agonists, have no potential for either abuse or diversion, and are not controlled substances. The principle underlying naltrexone therapy: by blocking the reinforcing (euphoria producing) effects of opioids, drug taking is deprived of its rewards. Like binge eating after bariatric surgery, opiate use on a naltrexone block becomes an exercise in futility that over time extinguishes. It is worth noting, however, that because naltrexone is a competitive antagonist that binds reversibly to opioid receptors, exposure to very high doses of opioids, especially high affinity drugs (e. g., fentanyl, heroin), has the potential to overcome naltrexone at the receptor site and drown out its protective effects.
1 Naltrexone has been available as a daily-dose tablet for the treatment of opioid (as well as alcohol) dependence for more than 30 years. But with few exceptions, it is difficult for individuals with a history of opioid use disorders to make the "one good decision a day" (Skolnick and Volkow 2012) to remain abstinent by adhering to a regimen of oral naltrexone (Fram, Marmo, and Holden 1989) . In 2010, an ER injection of naltrexone (Vivitrol®) was approved for prevention of relapse to opioid dependence. This intramuscular formulation, generally administered in the buttocks, results in naltrexone levels that block the euphoria produced by opioids for about one month.
Evidence for Antagonist-based MAT in Non-offenders
In individuals with OUDs, the efficacy of ER naltrexone was demonstrated in a double-blind, placebo controlled trial of 250 patients who had been recently detoxified and opioid free for at least 7 days (Krupitsky et al. 2011 Lancet) . Before initiating ER naltrexone, participants were required to pass a naloxone challenge -parenteral administration of a low dose (e. g., 50 micrograms, IV) of naloxone, a short acting opioid antagonist, followed by an evaluation of vital signs and opioid withdrawal symptoms -to ensure that they were no longer physically dependent on opioids, and to avoid the severe and protracted withdrawal that could result from administering a long-lasting antagonist to an opioid dependent individual. During the trial, patients received monthly injections of either ER naltrexone or placebo for 6 months, together with 12 counseling sessions. The primary endpoint was abstinence between weeks 5-24 (measured by urine analysis and self-report); among the secondary endpoints were self-reported opioid free days, number of days in treatment, and craving scores. Patients receiving ER naltrexone had a significantly higher proportion of weeks of confirmed abstinence (90 %) compared to placebo (35 %; p = 0.0002). The median retention time in treatment was significantly increased (p = 0.0042) in the naltrexone group (168 days compared with 96 days in patients receiving placebo), and there was a significant reduction in craving in naltrexone treated patients (p < 0.0001) compared to individuals receiving placebo. Naloxone challenge confirmed there had been a relapse to opioid dependence in 17 patients receiving placebo compared with 1 patient in the ER naltrexone cohort (p < 0.0001). An even longer-lasting form of naltrexone has also shown promise. In Russia (where agonist MAT is not currently available), a naltrexone implant that delivers medication for up to 2 months was tested in a trial of 306 opioid addicted patients who recently underwent detoxification. This study employed a 'double dummy' design to compare the effects of this 1000 mg naltrexone implant to oral naltrexone and placebo; that is, patients receiving the active implant also received oral placebo; patients receiving oral naltrexone (50 mg) also received a placebo implant; and patients in the placebo arm received both a placebo implant and placebo tablets. At the end of study (24 weeks), 54 of 102 patients (52.9 %) receiving the implant remained in treatment without relapse compared with 16 of 102 (15.7 %) patients receiving oral naltrexone and 11 of 102 patients receiving placebo (10.8 %), respectively (Krupitsky et al. 2012) . These implants are inserted under the skin and require surgical implantation, but are biodegradable and do not require removal. While it is not known if these implants will be approved by the Food & Drug Administration (FDA), a longer duration implant could provide another treatment option for individuals with OUDs.
Evidence for Antagonist-based MAT in Offenders
In offenders with OUDs, specifically community-dwelling adults who had been incarcerated and had a history of opioid dependence, Lee et al. (2016) compared monthly injections of ER naltrexone to treatment as usual (brief counseling and referrals for community treatment programs) for 24 weeks.
This randomized, open label study was conducted in~300 volunteers who expressed a preference not to receive agonist (maintenance) therapy. During the 24 week treatment phase, individuals assigned to the ER naltrexone arm had a significantly longer median time to relapse (10.5 weeks versus 5.0 weeks; p < 0.001), a lower relapse rate (43 % versus 64 % of participants; p < 0.001) risks associated with agonist-based MAT use during pregnancy are well-documented: Agonistbased MAT use during pregnancy is linked to adverse effects to the fetus and newborn, including physical dependence and withdrawal, retardation of growth, and neonatal respiratory depression at high doses. Perhaps the best described of these effects is neonatal abstinence syndrome (NAS), which has been found to be associated with both buprenorphine and methadone treatment (Jones et al. 2010) . Notably, the incidence of NAS has risen dramatically over the past decade: between 2004 and 2013, neonatal ICU admissions of NAS patients increased almost four-fold, from 7 to 27 cases/1000 admissions (Tolia et al. 2015) .
defined as 10 (or more) days of opioid use in a 28 day period, and a higher rate of opioid negative urines (74 % versus 56 %, p < 0.001) compared to treatment as usual. However, there did not appear to be a sustained "carry-over" effect of naltrexone, since at study week 78 (approximately 1 year after cessation of treatment), the rates of opioid-negative urines were identical (46 %) in both groups. There were also significantly fewer overdoses in the ER naltrexone arm of the study. Tolerance develops to the pharmacological actions of opioids so that, over time, ever increasing doses of opioids are required to produce a "high." This tolerance enables dependent individuals to consume quantities of opioids that would produce a fatal respiratory depression in naïve individuals. But when opioids are no longer consumed, this tolerance is gradually lost. Thus, CJ offenders with OUDs who have been recently released from incarceration are at an increased risk for overdose (Binswanger et al. 2007) . Despite low statistical power to detect uncommon events in the Lee et al. (2016) study, the rate of overdose events in the treatment as usual group was significantly higher than patients receiving ER naltrexone (7 versus 0, p < 0.02; 5 of these overdoses were fatal). Although there was no statistically significant difference in the rate of re-incarceration between these groups, the percent of subjects reincarcerated (35 % versus 45 %), the total days of incarceration (1651 versus 2628) and the days incarcerated per participant (11.1 versus 17.6) were all lower in individuals receiving ER naltrexone (Lee et al. 2016) . While these findings require replication in a larger population, the reduction found in both overdose events and total days of re-incarceration provide compelling evidence for ER naltrexone in this population.
Relative Affordability of Antagonist-based MAT
While affordable compared to some other life-saving medications (eg., cancer chemotherapies (Kantarjian et al. 2014) ), ER naltrexone is expensive compared to generic, agonist-based therapies, which is a major factor inhibiting its broad-based adoption. Incarcerated individuals with OUDs, however, are often denied access to even these cheap agonist-based options. Moreover, despite the substantially higher cost of ER naltrexone relative to generic agonists, it is associated with lower overall annual healthcare costs per patient than either methadone (-$8,170) or buprenorphine (-$1,467) (Baser et al. 2011 ). This report, together with the findings of Lee et al. (2016) in CJ offenders, strengthens the case for ER naltrexone as an important element in the reintegration of offenders with a history of OUDs. Yet such a policy can be One Good Decision justified only if healthcare and societal costs are viewed "holistically," rather than siloing these into (e. g.) pharmacy costs, hospital costs, and the costs associated with re-incarcerating these individuals.
Why Offenders may be Especially Good Candidates
Individuals under criminal-justice system supervision may be especially good candidates for ER naltrexone, for several reasons. As noted above, to start treatment on ER naltrexone a person would have stop taking opiates and overcome any physiological dependence. Through forced abstinence behind bars, most offenders meet this eligibility criterion. (Notably, this also complicates the decision to reexpose an already abstinent person to opiates with agonist-based MATs.) Second, given the well-established link between alcohol and crime (Graham and West 2001) , as well as the prevalence of polydrug use among criminal justice populations (Mumola and Karberg 2006) , ER naltrexone's dual indication for opioid and alcohol dependence could prove beneficial in this population. Third, a person's 'motivation' has been shown to play a key role in adherence to treatments delivered in the CJ setting, which in turn predicts treatment success (De Leon, Melnick, and Hawke 1999) . This provides yet another unique justification for ER naltrexone, since adherence to it requires motivation for just one good decision a month.
Ethical Implication of Brain Disease Model of Addiction
Despite the evidence, one might still question whether the use of MAT in the CJ setting is ethical. For example: given the potential for coercion, can an offender freely choose ER naltrexone as a condition of probation or parole? Such moral quandaries have been thoroughly debated (O'Brien and Cornish 2006) . To this debate we offer a single point to consider. After decades of research, the brain disease model of addiction has gained widespread, if not universal (Hall, Carter, and Forlini 2015) , support from the biomedical research community. Its central tenet is that addiction co-opts the brain, making it difficult for addicts to control their decisions, either to misuse drugs or to seek treatment (Volkow and Morales 2015) . For offenders with an OUD, then, perhaps of equal concern is the coercive effect of addiction itself -and that for such individuals access to MAT in CJ setting would be better viewed as an option to regain control.
